Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 27:15:290.
doi: 10.1186/s12879-015-1019-4.

Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis

Maya Graham Pedersen  1 , Søren Jensen-Fangel  2 , Hanne Vebert Olesen  3 , San Deep Prataprao Tambe  4 , Eskild Petersen  5
Affiliations

Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis

Maya Graham Pedersen et al. BMC Infect Dis. .

Abstract

Background: To determine complications during outpatient parenteral antimicrobial therapy (OPAT) administrated through a peripheral venous line, PICC-line or PORT-A-CATH (PAC).

Methods: Catheter related complications in patients with cystic fibrosis during OPAT were identified through a retrospective review of patient files supplemented by an interview.

Results: In 64 treatment episodes with a peripheral venous line, 51 (79.7 %) used bolus injection and 13 (20.3 %) used infusion pump. 27 out of 51 (53.0 %) bolus injection episodes experienced complications, which required removal. None were observed for infusion pump treatments. The infectious complications requiring removal of peripheral venous line were 9 out of 23 (39.1 %) for the PICC line and 11 out of 26 (42.3 %) for the PAC. No anaphylaxis was observed during the OPAT treatments.

Conclusions: Our data indicate that using an infusion pump to administer the antibiotic treatment minimized peripheral venous line complications. The frequency of complications leading to removal of the catheter is about the same for PICC-lines and PACs, but the average life-time of the latter is much longer. Allergic reactions are not a major problem.

PubMed Disclaimer

References

    1. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros. 2005;4:3–5. doi: 10.1016/j.jcf.2005.05.005. - DOI - PubMed
    1. Yankaskas JR, Knowles MR, Boat TF. Cystic fibrosis in adults. Philadelphia: Lippincott-Raven Publishers; 1999.
    1. Döring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11:461–79. doi: 10.1016/j.jcf.2012.10.004. - DOI - PubMed
    1. Hammond LJ, Caldwell S, Campbell PW. Cystic fibrosis, intravenous antibiotics and home therapy. J Pediatr Health Care. 1991;5:24–30. doi: 10.1016/0891-5245(91)90044-Q. - DOI - PubMed
    1. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, et al. Practice guidelines for outpatient parenteral. Clin Infect Dis. 2004;38:1651–72. doi: 10.1086/420939. - DOI - PubMed

Substances